Physician profile
Daniel P Freeman
NPI 1336107374
$12,238.75
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,916 · 2020: $2,552 · 2021: $2,670 · 2022: $2,165 · 2023: $1,511 · 2024: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,809.46 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Emd Serono, INC. | $1,343.41 | 2019-2024 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $1,338.45 | 2019-2021 | |
| Amgen INC. | $1,042.45 | 2019-2022 | |
| Biogen, INC. | $989.96 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $868.94 | 2019-2024 | Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $805.86 | 2019-2023 | |
| Abbvie INC. | $588.63 | 2021-2024 | |
| Lilly USA, LLC | $418.26 | 2019-2023 | Reyvow, Emgality, Amyvid |
| Neurocrine Biosciences, INC. | $277.49 | 2019-2024 | Ingrezza, Ongentys |
| Genzyme Corporation | $275.46 | 2019-2023 | |
| Sk Life Science, INC. | $241.07 | 2020-2024 | |
| Eisai INC. | $238.90 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $222.24 | 2020-2022 | |
| Celgene Corporation | $203.21 | 2021-2023 | Zeposia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $198.26 | 2020-2023 | Vyepti |
| Allergan, INC. | $189.01 | 2020 | |
| Argenx US, INC. | $146.05 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Upsher-Smith Laboratories LLC | $130.23 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $111.74 | 2021 | |
| Pfizer INC. | $108.71 | 2023-2024 | |
| Arbor Pharmaceuticals, INC. | $95.30 | 2020-2021 | |
| Neurelis, INC. | $80.82 | 2020-2022 | |
| Genentech USA, INC. | $77.90 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $76.11 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $65.51 | 2022 | |
| Adamas Pharmaceuticals, INC. | $63.76 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.85 | 2020-2021 | |
| Catalyst Pharmaceuticals, INC. | $40.57 | 2023 | Firdapse, Fycompa |
| Livanova USA, INC. | $19.34 | 2019 | |
| Banner Life Sciences, LLC | $19.10 | 2022 | |
| Greenwich Biosciences, INC. | $18.45 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.37 | 2024 | |
| Amneal Pharmaceuticals LLC | $15.91 | 2021 | |
| Alnylam Pharmaceuticals INC. | $15.12 | 2022 | |
| Vanda Pharmaceuticals INC. | $13.04 | 2019 | |
| Tanabe Pharma America, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.